Altered Cell Surface N-Glycosylation of Resting and Activated T Cells in Systemic Lupus Erythematosus

• Main Authors: Enikő Szabó, Ákos Hornung, Éva Monostori, Márta Bocskai, Ágnes Czibula, László Kovács
• Format: Article
• Language: English
• Published: MDPI AG 2019-09-01
• Series: International Journal of Molecular Sciences
• Subjects: systemic lupus erythematosus; T cells; glycosylation; sialylation; lectin binding; glycosylation enzymes; galectin 1
• Online Access: https://www.mdpi.com/1422-0067/20/18/4455

Altered cell surface glycosylation in congenital and acquired diseases has been shown to affect cell differentiation and cellular responses to external signals. Hence, it may have an important role in immune regulation; however, T cell surface glycosylation has not been studied in systemic lupus erythematosus (SLE), a prototype of autoimmune diseases. Analysis of the glycosylation of T cells from patients suffering from SLE was performed by lectin-binding assay, flow cytometry, and quantitative real-time PCR. The results showed that resting SLE T cells presented an activated-like phenotype in terms of their glycosylation pattern. Additionally, activated SLE T cells bound significantly less galectin-1 (Gal-1), an important immunoregulatory lectin, while other lectins bound similarly to the controls. Differential lectin binding, specifically Gal-1, to SLE T cells was explained by the increased gene expression ratio of sialyltransferases and neuraminidase 1 (<i>NEU1</i>), particularly by elevated ST6 beta-galactosamide alpha-2,6-sialyltranferase 1 (<i>ST6GAL1</i>)/<i>NEU1</i> and ST3 beta-galactoside alpha-2,3-sialyltransferase 6 (S<i>T3GAL6)</i>/<i>NEU1</i> ratios. These findings indicated an increased terminal sialylation. Indeed, neuraminidase treatment of cells resulted in the increase of Gal-1 binding. Altered T cell surface glycosylation may predispose the cells to resistance to the immunoregulatory effects of Gal-1, and may thus contribute to the pathomechanism of SLE.